a test article for that "blog network" thing (1,2) (now that WestLB is closing (1,2) I might as well fill the gap in the Düsseldorf equity research landscape ...).
I think it might be a good idea to buy a few shares of the following European biopharma companies.
Algeta (1), Galapagos (1,2), MorphoSys (1), Qiagen (1,2).
main drug candidate: Alpharadin (radium-223 chloride)
pivotal phase III trial: ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer)
clinicaltrials.gov information: A Phase III Study of Alpharadin (Radium-223)in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (ALSYMPCA)
September 21, 2011 - ESMO 2011 presentation - Overall Survival Benefit of Radium-223 Chloride (Alpharadin) in the Treatment of Patients With Symptomatic Bone Metastases in Castration-Resistant Prostate Cancer (CRPC): A Phase III Randomised Trial (ALSYMPCA) (pdf)
Øyvind S. Bruland - Professor of Clinical Oncology, Faculty of Medicine, University of Oslo - Alpharadin page
March 4, 2009 - talk on Alpharadin (pdf)
September 24, 2011 - Positive Phase III Data on Bayer’s Investigational Drug Alpharadin Show Significant Increase in Overall Survival
October 15, 2011 - International Prostate Cancer Studies Report Inroads in Managing Bone Metastases
Dr. Chris Parker: Radium–223 Will Change Practice in Metastatic Prostate Cancer
Algeta - Third Quarter 2011 Report (pdf)
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again
Leverkusen, December 20, 2011
Another two hopeful candidates in oncology
In oncology, Bayer has achieved important progress with Alpharadin and regorafenib. "Both active ingredients exhibited significant improvement of overall survival in trials," said Dekkers. This result was achieved both by Alpharadin in the treatment of prostate cancer with bone metastases and regorafenib in the treatment of advanced colorectal cancer.
Alpharadin is a novel substance to treat forms of cancer which have spread to the bone. Its efficacy in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastasis has been successfully tested in a pivotal Phase III trial. Alpharadin has been granted Fast Track status by the U.S. Food and Drug Administration, which means that the drug product can be reviewed in a simplified procedure. Bayer plans to submit the registration dossier in the United States and Europe in mid-2012. This product licensed in from Algeta ASA could also have blockbuster potential if it receives marketing authorization in further indications.
Leverkusen and Düsseldorf almost "touch", so I guess I could call Alpharadin a "Düsseldorf area drug", hehe ...